Cost‐utility of omalizumab for the treatment of uncontrolled moderate‐to‐severe persistent pediatric allergic asthma in a middle‐income country-Reference-Cited by-同舟云学术

Cost‐utility of omalizumab for the treatment of uncontrolled moderate‐to‐severe persistent pediatric allergic asthma in a middle‐income country

Published:2021-06-24 Issue:9 Volume:56 Page:2987-2996
ISSN:8755-6863
Container-title:Pediatric Pulmonology
language:en
Short-container-title:Pediatric Pulmonology

Author:

Rodriguez‐Martinez Carlos E.¹²^ORCID,Sossa‐Briceño Monica P.³,Castro‐Rodriguez Jose A.⁴^ORCID

Affiliation:

1. Department of Pediatrics School of Medicine, Universidad Nacional de Colombia Bogota Colombia

2. Department of Pediatric Pulmonology, School of Medicine Universidad El Bosque Bogota Colombia

3. Department of Internal Medicine, School of Medicine Universidad Nacional de Colombia

4. Division of Pediatrics, Department of Pediatric Pulmonology and Cardiology, School of Medicine Pontificia Universidad Catolica de Chile Santiago Chile

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ppul.25541

Reference45 articles.

1. Prevalence of asthma and other allergic conditions in Colombia 2009–2010: a cross-sectional study

2. Epidemiology of Asthma in Children and Adults

3. An international observational prospective study to determine the Cost Of Asthma eXacerbations (COAX)

4. Global Initiative for Asthma.Global Strategy for Asthma Management and Prevention;2020.www.ginasthma.org. Accessed February 4 2021.

5. British Thoracic Society. British guideline on the management of asthma.https://www.sign.ac.uk/assets/sign153.pdf

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biological treatments in childhood asthma;Current Opinion in Allergy & Clinical Immunology;2024-04-01

2. Cost effectiveness of omalizumab for severe asthma in Colombia;Journal of Asthma;2023-10-10

3. Effects of omalizumab combined with budesonide formoterol on clinical efficacy, pulmonary function, immune function, and adverse reactions in children with moderate and severe allergic asthma;Allergologia et Immunopathologia;2023-07-01

4. Cost‐effectiveness of omalizumab for the treatment of severe pediatric allergic asthma—Results of a real‐life study in Spain;Pediatric Allergy and Immunology;2023-04

5. Incremental net monetary benefit of biologic therapies in moderate to severe asthma: a systematic review and meta-analysis of economic evaluation studies;Journal of Asthma;2023-03-16